Anavex Life Sciences (AVXL) 1.8500 $AVXL
Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference
GlobeNewswire - Wed Oct 07, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain from November 5-7, 2015. The late-breaking oral session will be presented by the trial's Principal Investigator, Stephen Macfarlane, FRANZCP, Director and Associate Professor, Aged Psychiatry at Caulfield Hospital in Melbourne, Australia.
Anavex to announce uplisting to Nasdaq & reverse stock split
M2 - Wed Oct 07, 3:11AM CDT
Biopharmaceutical company Anavex Life Sciences (OtherOTC:AVXL) revealed on Tuesday that it has submitted and finalised its application for the uplisting of its common stock to the NASDAQ Capital Market.
CORRECTING and REPLACING -- Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
GlobeNewswire - Tue Oct 06, 4:20PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market. To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares. The Company's common stock will begin trading on a post-split basis at the opening of trading on October 7, 2015.
Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
GlobeNewswire - Tue Oct 06, 3:05PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market. To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares. The Company's common stock will begin trading on a post-split basis at the opening of trading on October 7, 2015.
DUE DILIGENCE REPORT: Anavex Life Sciences Completes Enrollment for Clinical Phase 2a - BrokerBank Securities
PR Newswire - Tue Oct 06, 12:45PM CDT
Anavex Life Sciences Corp. (OTCQX: AVXL) shares closed at $1.90 yesterday, up 18.44%. Trading volume exceeded the 30 day average by a factor of three. The AVXL share price has been on a significant rise since July.
Penny Stocks BUZZ for Hemp, Terra Tech, Medical Marijuana, NORTH AMERICAN CANNABIS HOLDINGS, Anavex Life Sciences, and Energizer Tennis
PR Newswire - Thu Oct 01, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hemp (OTCMKTS:HEMP), Terra Tech (OTCMKTS:TRTC), Medical Marijuana (OTCMKTS:MJNA), NORTH AMERICAN CANNABIS HOLDINGS (OTCMKTS:USMJ), Anavex Life Sciences (OTCMKTS:AVXL), and Energizer Tennis (OTCBB:EZRT).
Penny Stocks Alerts for Clean Coal Technologies, TOTALLY HEMP CRAZY, Global Equity, GT Advanced Technologies, NuGene, and Anavex Life Sciences
PR Newswire - Wed Sep 30, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Clean Coal Technologies (OTCMKTS:CCTC), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), Global Equity (OTCBB:GEQU), GT Advanced Technologies (OTCMKTS:GTATQ), NuGene (OTCBB:NUGN), and Anavex Life Sciences (OTCMKTS:AVXL).
Anavex Completes Patient Enrollment for Phase 2a Alzheimer's Trial Ahead of Schedule
GlobeNewswire - Mon Sep 28, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that patient enrollment for the Phase 2a clinical trial of ANAVEX 2-73 has been completed ahead of schedule. With the Phase 2a trial now fully enrolled, Anavex expects to release topline data for PART A before the end of the year.
Anavex to Present at 2015 Ladenburg Thalmann Healthcare Conference
GlobeNewswire - Wed Sep 23, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29, 2015 at 4 p.m. ET in Track 1. The conference will be held at the Sofitel Hotel in New York City.
Anavex Appoints International Alzheimer's Expert to Scientific Advisory Board
GlobeNewswire - Mon Sep 21, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Harald Hampel, MD, MA, PhD, MSc, to the Company's Scientific Advisory Board. An internationally recognized expert on Alzheimer's and related neurodegenerative diseases, Dr. Hampel is Professor and AXA Research Fund Chair at Sorbonne Universities' Pierre and Marie Curie University (UPMC) in Paris, the leading university in science, technology and medicine in France. The AXA-UPMC Chair is hosted within the highly specialized Institute for Memory and Alzheimer's Disease (IM2A), a reference center for Alzheimer's and other neurodegenerative diseases, and affiliated with a leading neuroscience institution, the Brain and Spine Institute (ICM), as well as the Department of Neurology at the Pitie-Salpetriere University Hospital.
Global Biopharmaceuticals Industry
PR Newswire - Tue Aug 25, 2:30PM CDT
This report analyzes the worldwide markets for Biopharmaceuticals in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 514 companies including many key and niche players such as -
ABBV: 55.64 (-0.40)
Pancreatic Cancer Pipeline Review: H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Pancreatic Cancer
M2 - Mon Aug 17, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tnfhf/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Pancreatic Cancer Overview - Therapeutics Development - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development - Pancreatic Cancer - Therapeutics Assessment - Drug Profiles - Pancreatic Cancer - Recent Pipeline Updates - Pancreatic Cancer - Dormant Projects - Pancreatic Cancer - Discontinued Products - Pancreatic Cancer - Product Development Milestones Companies Mentioned - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Ambryx Biotechnology, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation For more information visit http://www.researchandmarkets.com/research/7t...tic_cancer
ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), AMBX: (), AMGN: 149.59 (-0.31), ADMP: 4.00 (-0.05), ABBV: 55.64 (-0.40)
Anavex Reports Fiscal Third Quarter 2015 Financial Results
GlobeNewswire - Mon Aug 17, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today reported financial results for the three and nine months ended June 30, 2015.
Ovarian Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Ovarian Cancer
M2 - Mon Aug 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/752ksw/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Ovarian Cancer - Pipeline Review, H1 2015', provides an overview of the Ovarian Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: Overview Therapeutics Development Therapeutics under Development by Companies Therapeutics under Investigation by Universities/Institutes Pipeline Products Glance Products under Development by Companies Products under Investigation by Universities/Institutes Companies Involved in Therapeutics Development Therapeutics Assessment Drug Profiles Recent Pipeline Updates Dormant Projects Discontinued Products Product Development Milestones Companies Mentioned - 3-V Biosciences, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abeona Therapeutics, Inc. - AbGenomics International, Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advantagene, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Agilvax, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Amorfix Life Sciences Ltd. - Anavex Life Sciences Corp. - Angstrom Pharmaceuticals, Inc. - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aprea AB - arGEN-X BV - Armour Therapeutics Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. For more information visit http://www.researchandmarkets.com/research/75...ian_cancer
ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), AMBX: (), AMGN: 149.59 (-0.31), ABEO: 4.44 (+0.22), AAAP: (), ABBV: 55.64 (-0.40), PMN.TO: 0.08 (+0.01), ARRY: 5.09 (+0.13), XLRN: 24.08 (-0.18)
Colon Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colon Cancer and Enlists all Their Major and Minor Projects
M2 - Fri Aug 14, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6lqjnr/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Colon Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Apogenix GmbH - Aposense Ltd. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bavarian Nordic A/S - Bio-Path Holdings, Inc. - Bioncotech Therapeutics S.L. - Bionomics Limited - Carna Biosciences, Inc. - Celyad - Cold Genesys, Inc. For more information visit http://www.researchandmarkets.com/research/6l...lon_cancer
ADRO: 22.06 (+0.32), BPTH: 1.22 (+0.06), AMBX: (), AZN: 32.23 (-0.16), CYAD: 38.00 (+0.15)
Anavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73
GlobeNewswire - Wed Aug 12, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property (IP) protection until at least 2035. ANAVEX2-73 is the subject of an ongoing Phase 2a clinical trial for the treatment of Alzheimer's disease.
The Shorts are Fueling Massive Aquinox Run
M2 - Mon Aug 10, 9:23AM CDT
Aquinox Pharmaceuticals (AQXP) closed near 5 bagger territory for Friday's session, looking more like the response we've come to appreciate from the quality OTC listings. Over 62 million shares traded after the release of positive mid-stage trial results for its AQX-1125 inflammation therapy, for patients with bladder pain syndrome or interstitial cystitis, being the catalyst for Canadian drug company. In pre-market trading, the shares blew through its 52 week high of $12.08, so look for clear skies in today's session, but keep a tight stop since it is overextended.
AQXP: 12.90 (+0.11)
Anavex Awarded Grant From The Michael J. Fox Foundation for Parkinson's Research
GlobeNewswire - Mon Aug 10, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to develop ANAVEX 2-73 for the treatment of Parkinson's disease.
Penny Stocks Alerts for TOTALLY HEMP CRAZY, America Resources Exploration, Eventure Interactive, Arch Therapeutics, Anavex Life Sciences, and Terra Tech
PR Newswire - Thu Jul 30, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: TOTALLY HEMP CRAZY (OTCMKTS:THCZ), America Resources Exploration (OTCBB:AREN), Eventure Interactive (OTCBB:EVTI), Arch Therapeutics (OTCBB:ARTH), Anavex Life Sciences (OTCMKTS:AVXL), and Terra Tech (OTCMKTS:TRTC).
Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference
GlobeNewswire - Wed Oct 07, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain from November 5-7, 2015. The late-breaking oral session will be presented by the trial's Principal Investigator, Stephen Macfarlane, FRANZCP, Director and Associate Professor, Aged Psychiatry at Caulfield Hospital in Melbourne, Australia. Anavex to announce uplisting to Nasdaq & reverse stock split
M2 - Wed Oct 07, 3:11AM CDT
Biopharmaceutical company Anavex Life Sciences (OtherOTC:AVXL) revealed on Tuesday that it has submitted and finalised its application for the uplisting of its common stock to the NASDAQ Capital Market.
CORRECTING and REPLACING -- Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
GlobeNewswire - Tue Oct 06, 4:20PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market. To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares. The Company's common stock will begin trading on a post-split basis at the opening of trading on October 7, 2015. Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
GlobeNewswire - Tue Oct 06, 3:05PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market. To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares. The Company's common stock will begin trading on a post-split basis at the opening of trading on October 7, 2015. DUE DILIGENCE REPORT: Anavex Life Sciences Completes Enrollment for Clinical Phase 2a - BrokerBank Securities
PR Newswire - Tue Oct 06, 12:45PM CDT
Anavex Life Sciences Corp. (OTCQX: AVXL) shares closed at $1.90 yesterday, up 18.44%. Trading volume exceeded the 30 day average by a factor of three. The AVXL share price has been on a significant rise since July.
Penny Stocks BUZZ for Hemp, Terra Tech, Medical Marijuana, NORTH AMERICAN CANNABIS HOLDINGS, Anavex Life Sciences, and Energizer Tennis
PR Newswire - Thu Oct 01, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hemp (OTCMKTS:HEMP), Terra Tech (OTCMKTS:TRTC), Medical Marijuana (OTCMKTS:MJNA), NORTH AMERICAN CANNABIS HOLDINGS (OTCMKTS:USMJ), Anavex Life Sciences (OTCMKTS:AVXL), and Energizer Tennis (OTCBB:EZRT).
Penny Stocks Alerts for Clean Coal Technologies, TOTALLY HEMP CRAZY, Global Equity, GT Advanced Technologies, NuGene, and Anavex Life Sciences
PR Newswire - Wed Sep 30, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Clean Coal Technologies (OTCMKTS:CCTC), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), Global Equity (OTCBB:GEQU), GT Advanced Technologies (OTCMKTS:GTATQ), NuGene (OTCBB:NUGN), and Anavex Life Sciences (OTCMKTS:AVXL).
Anavex Completes Patient Enrollment for Phase 2a Alzheimer's Trial Ahead of Schedule
GlobeNewswire - Mon Sep 28, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that patient enrollment for the Phase 2a clinical trial of ANAVEX 2-73 has been completed ahead of schedule. With the Phase 2a trial now fully enrolled, Anavex expects to release topline data for PART A before the end of the year. Anavex to Present at 2015 Ladenburg Thalmann Healthcare Conference
GlobeNewswire - Wed Sep 23, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29, 2015 at 4 p.m. ET in Track 1. The conference will be held at the Sofitel Hotel in New York City. Anavex Appoints International Alzheimer's Expert to Scientific Advisory Board
GlobeNewswire - Mon Sep 21, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the appointment of Harald Hampel, MD, MA, PhD, MSc, to the Company's Scientific Advisory Board. An internationally recognized expert on Alzheimer's and related neurodegenerative diseases, Dr. Hampel is Professor and AXA Research Fund Chair at Sorbonne Universities' Pierre and Marie Curie University (UPMC) in Paris, the leading university in science, technology and medicine in France. The AXA-UPMC Chair is hosted within the highly specialized Institute for Memory and Alzheimer's Disease (IM2A), a reference center for Alzheimer's and other neurodegenerative diseases, and affiliated with a leading neuroscience institution, the Brain and Spine Institute (ICM), as well as the Department of Neurology at the Pitie-Salpetriere University Hospital. Global Biopharmaceuticals Industry
PR Newswire - Tue Aug 25, 2:30PM CDT
This report analyzes the worldwide markets for Biopharmaceuticals in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 514 companies including many key and niche players such as -
ABBV: 55.64 (-0.40)
Pancreatic Cancer Pipeline Review: H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Pancreatic Cancer
M2 - Mon Aug 17, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7tnfhf/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H1 2015" report to their offering. Summary This report provides comprehensive information on the therapeutic development for Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Pancreatic Cancer Overview - Therapeutics Development - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development - Pancreatic Cancer - Therapeutics Assessment - Drug Profiles - Pancreatic Cancer - Recent Pipeline Updates - Pancreatic Cancer - Dormant Projects - Pancreatic Cancer - Discontinued Products - Pancreatic Cancer - Product Development Milestones Companies Mentioned - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Ambryx Biotechnology, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation For more information visit http://www.researchandmarkets.com/research/7t...tic_cancer
ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), AMBX: (), AMGN: 149.59 (-0.31), ADMP: 4.00 (-0.05), ABBV: 55.64 (-0.40)
Anavex Reports Fiscal Third Quarter 2015 Financial Results
GlobeNewswire - Mon Aug 17, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today reported financial results for the three and nine months ended June 30, 2015. Ovarian Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Ovarian Cancer
M2 - Mon Aug 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/752ksw/ovarian_cancer) has announced the addition of the "Ovarian Cancer - Pipeline Review, H1 2015" report to their offering. Summary This, Ovarian Cancer - Pipeline Review, H1 2015', provides an overview of the Ovarian Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: Overview Therapeutics Development Therapeutics under Development by Companies Therapeutics under Investigation by Universities/Institutes Pipeline Products Glance Products under Development by Companies Products under Investigation by Universities/Institutes Companies Involved in Therapeutics Development Therapeutics Assessment Drug Profiles Recent Pipeline Updates Dormant Projects Discontinued Products Product Development Milestones Companies Mentioned - 3-V Biosciences, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abeona Therapeutics, Inc. - AbGenomics International, Inc. - Acceleron Pharma, Inc. - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advantagene, Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - Aeterna Zentaris Inc. - Agilvax, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Almac Discovery Limited - Ambrx, Inc. - Amgen Inc. - Amorfix Life Sciences Ltd. - Anavex Life Sciences Corp. - Angstrom Pharmaceuticals, Inc. - ANP Technologies, Inc. - Aphios Corporation - Aposense Ltd. - Aprea AB - arGEN-X BV - Armour Therapeutics Inc. - Arog Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. For more information visit http://www.researchandmarkets.com/research/75...ian_cancer
ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), AMBX: (), AMGN: 149.59 (-0.31), ABEO: 4.44 (+0.22), AAAP: (), ABBV: 55.64 (-0.40), PMN.TO: 0.08 (+0.01), ARRY: 5.09 (+0.13), XLRN: 24.08 (-0.18)
Colon Cancer Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Colon Cancer and Enlists all Their Major and Minor Projects
M2 - Fri Aug 14, 8:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6lqjnr/colon_cancer) has announced the addition of the "Colon Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Colon Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities Key Topics Covered: - Introduction - Colon Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - Aduro BioTech, Inc. - Advanced Proteome Therapeutics Corporation - Advenchen Laboratories, LLC - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - AlphaVax, Inc. - Ambrx, Inc. - Anavex Life Sciences Corp. - AndroScience Corporation - ANP Technologies, Inc. - Aphios Corporation - Apogenix GmbH - Aposense Ltd. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bavarian Nordic A/S - Bio-Path Holdings, Inc. - Bioncotech Therapeutics S.L. - Bionomics Limited - Carna Biosciences, Inc. - Celyad - Cold Genesys, Inc. For more information visit http://www.researchandmarkets.com/research/6l...lon_cancer
ADRO: 22.06 (+0.32), BPTH: 1.22 (+0.06), AMBX: (), AZN: 32.23 (-0.16), CYAD: 38.00 (+0.15)
Anavex Receives Notice of Allowance for U.S. Patent Application Related to ANAVEX 2-73
GlobeNewswire - Wed Aug 12, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Pat. App. No. 14/205,637 related to ANAVEX 2-73. Upon issuance, the patent will provide intellectual property (IP) protection until at least 2035. ANAVEX2-73 is the subject of an ongoing Phase 2a clinical trial for the treatment of Alzheimer's disease. The Shorts are Fueling Massive Aquinox Run
M2 - Mon Aug 10, 9:23AM CDT
Aquinox Pharmaceuticals (AQXP) closed near 5 bagger territory for Friday's session, looking more like the response we've come to appreciate from the quality OTC listings. Over 62 million shares traded after the release of positive mid-stage trial results for its AQX-1125 inflammation therapy, for patients with bladder pain syndrome or interstitial cystitis, being the catalyst for Canadian drug company. In pre-market trading, the shares blew through its 52 week high of $12.08, so look for clear skies in today's session, but keep a tight stop since it is overextended.
AQXP: 12.90 (+0.11)
Anavex Awarded Grant From The Michael J. Fox Foundation for Parkinson's Research
GlobeNewswire - Mon Aug 10, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to develop ANAVEX 2-73 for the treatment of Parkinson's disease. Penny Stocks Alerts for TOTALLY HEMP CRAZY, America Resources Exploration, Eventure Interactive, Arch Therapeutics, Anavex Life Sciences, and Terra Tech
PR Newswire - Thu Jul 30, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: TOTALLY HEMP CRAZY (OTCMKTS:THCZ), America Resources Exploration (OTCBB:AREN), Eventure Interactive (OTCBB:EVTI), Arch Therapeutics (OTCBB:ARTH), Anavex Life Sciences (OTCMKTS:AVXL), and Terra Tech (OTCMKTS:TRTC).
